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ABSTRACT
Serotype distribution and antibiotic resistance (AR) among group B streptococci (GBS) affect GBS
disease prevention strategies, but vary among patient groups. A multiplex PCR-based reverse line blot
(mPCR ⁄RLB) hybridisation assay was used to compare the distributions of GBS serotypes, serotype III
subtypes and AR-associated genes among 666 invasive isolates from 663 patients, divided into ﬁve age
groups: infants, early-onset (EO; 0–6 days) and late-onset (LO; 7–90 days); children (aged 3 months to
14 years); women of childbearing age (WCBA; aged 15–45 years); and other adults (males aged
>15 years; females aged >45 years). Serotypes Ia and V and serosubtype III-1 accounted for 60% of
infections. Serosubtype III-2, which corresponds to a virulent clone belonging to sequence type (ST)17,
was relatively uncommon overall (7%), but was associated strongly with LO infant infections, in which
it was signiﬁcantly more common than in adult infections (25 ⁄ 104 (24%) vs. 9 ⁄ 392 (2%), p <0.0001) or in
EO infections (25 ⁄ 104 (24%) vs. 14 ⁄ 155 (9%), p <0.005). Erythromycin resistance genes were found in
8% of all isolates (ermB 3%, ermA 2.5% and mefA ⁄E 2%), in 11–15% of isolates of serotypes II and V and
subtype III-1, but in none of the isolates of serosubtype III-2 (III-2, 0 ⁄ 49 vs. all others, 54 ⁄ 618 (9%),
p <0.04). In summary, the virulent serosubtype III-2 was associated strongly with LO infant GBS
infection, but was less likely than other serotypes or serosubtype III-1 to carry AR genes.
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INTRODUCTION
Group B streptococci (GBS; Streptococcus agalactiae)
are a common cause of neonatal and obstetrical
sepsis, and are an increasingly important cause of
infection in the elderly and in patients with
chronic underlying medical conditions [1,2].
Infections in the elderly vary in severity from
mild urinary tract infections to life-threatening
sepsis and endocarditis [2]. The incidence of
neonatal sepsis has fallen signiﬁcantly over the
past decade, partly because of widespread use
of intra-partum antibiotic prophylaxis for GBS
carriers. Penicillin is the drug of choice for
prophylaxis and treatment of GBS disease, with
erythromycin and clindamycin recommended for
patients with a b-lactam allergy. However, wide-
spread intra-partum antibiotic prophylaxis is
likely to contribute to the emergence of anti-
biotic-resistant GBS [3]. There has been consider-
able progress in the development of conjugate
polysaccharide GBS vaccines [4], the formulation
of which depends on the distribution of GBS
serotypes. This varies among different patient
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groups, among geographical areas and over time.
Surveillance is an important adjunct to vaccine
development [5].
Previous reports have described the develop-
ment and evaluation of multiplex PCR-based
reverse line blot (mPCR ⁄RLB) assays for the
identiﬁcation of GBS molecular serotypes, sub-
types of molecular serotype (MS) III, and nine
antibiotic resistance (AR)-related markers [6,7].
In the present study, these assays were modiﬁed
and combined into a single mPCR ⁄RLB assay
and were used to test a large collection of
invasive GBS isolates from Australia and New
Zealand. MS III subtypes were also identiﬁed on
the basis of sequence variation in the cps gene
cluster [8]. The distribution of molecular sero-
types, MS III subtypes and AR markers was
compared among ﬁve patient groups over a
12-year period to provide important baseline
data before the introduction of a GBS vaccine
and to inform the clinical management of GBS
infections.
MATERIALS AND METHODS
Invasive GBS isolates
Invasive GBS isolates were obtained from 663 patients (605
isolates from blood, 35 from cerebrospinal ﬂuid (CSF), and 23
from joint ﬂuid or other normally sterile sites) between 1994
and 2005. All were serotyped at the Streptococcal Reference
Laboratory, Institute of Environmental Science & Research Ltd
(ESR), Kenepuru Science Centre, Porirua, New Zealand. Of the
663 isolates, 446 were from New Zealand; these comprised all
invasive isolates (excluding 15 that were non-viable) referred
to ESR for serotyping between 1994 and 2004 from laboratories
throughout New Zealand (population c. 4 million). The
remaining 217 isolates were from Australia; these comprised
all isolates cultured from normally sterile sites (excluding 11
that were non-viable) between 1996 and 2005 at the Centre for
Infectious Diseases and Microbiology (CIDM), Westmead,
NSW, Australia. The CIDM is a large diagnostic laboratory
providing services to a tertiary referral centre and several
district hospitals; these provide basic and specialised obstet-
rical and neonatal services, as well as basic (but not specialist)
paediatric services, for a population of c. 900 000 in western
Sydney.
GBS cases were classiﬁed into one of ﬁve groups (Table 1).
Infants with early-onset (EO) and late-onset (LO) disease were
those from whom GBS were isolated in the ﬁrst 6 days and
between 7 and 90 days following birth, respectively [9]. GBS
infections in children aged 3 months to 14 years were uncom-
mon and were grouped together. Women of childbearing age
(WCBA; aged 15–45 years) were considered separately; 27
women in this group were known to be pregnant or post-
partum, and it was assumed that this would also apply to a
signiﬁcant proportion of the remaining 66 women, for whom
this information was not available. Other adults included
males aged ‡15 years and females aged >45 years. The
distribution of isolates among patient groups in each country
is shown in Table 1.
mPCR ⁄RLB
This study combined two mPCR ⁄RLB assays described previ-
ously [6,7]. The ﬁnal assay incorporated one primer pair and
two species-speciﬁc probes for GBS, for each of its nine
serotypes, and for eight AR markers (18 primer pairs and 36
probes). Ampliﬁcation and hybridisation conditions were as
described previously [6,7]. MS III isolates were subtyped on
the basis of cps sequence variation and the presence of one or
more mobile genetic elements [8]. When discrepancies were
identiﬁed between conventional serotyping and molecular
serotyping (as determined by mPCR ⁄RLB), several colonies
from each isolate were tested separately by individual sero-
type-speciﬁc PCRs [6,10] and the conventional serotyping tests
were repeated, if necessary.
Statistical analysis
SPSS for Windows v.13.0 (SPSS Inc., Chicago, IL, USA) was
used for the statistical analyses. Chi-square and Fisher’s exact
tests were used, as appropriate, to compare differences in the
distribution of genetic markers among groups, with p <0.05
considered to be statistically signiﬁcant.
RESULTS
Comparison of conventional serotyping with
molecular serotyping by mPCR ⁄RLB
Seventy (11%) isolates were non-typeable by
conventional serotyping; these were divided
among the ﬁve patient groups as follows: EO,
17; LO, ﬁve; children, two; WCBA, eight; and
other adults, 37. These initially non-typeable
isolates were subsequently assigned by molecular
Table 1. Distribution into categories of 663 patients with
invasive disease caused by group B streptococci (GBS)a
Patient category (age)
Sydney (CIDM)b,
n (%)
New Zealand
(ESR)c, n (%)
Infant: early onset, neonatal
(aged <7 days)
44 (20) 109 (25)
Infant: late onset (aged 7–90 days)d 13 (6) 91 (20)
Children (aged 3 months to 14 years) 5 (2) 11 (2)
Women of childbearing age
(aged 15–45 years)
23 (11) 70 (16)
Other adults (males aged >15 years;
females aged >45 years)
133 (61) 164 (37)
Total 218 (100) 445 (100)
aDeﬁned as the isolation of GBS from a normally sterile site.
bThe CIDM (Centre for Infectious Diseases and Microbiology, Westmead, NSW,
Australia) provides diagnostic services to a tertiary referral hospital (with specialist
obstetrics and neonatal, but no paediatric, services) and several district hospitals in
western Sydney.
cESR (Institute of Environmental Science & Research, Pty Ltd, Porirua, NZ) is the
main public health reference laboratory in New Zealand.
dThe proportion of isolates from late-onset cases in Sydney was signiﬁcantly lower
than in New Zealand, because the CIDM does not provide microbiological services
to a specialist paediatric facility.
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serotyping to the following types: MS Ia, six (i.e.,
4% of the total number of 163 MS Ia isolates
identiﬁed by conventional serotyping and molec-
ular serotyping); Ib, 17 (20% of 87); II, ﬁve (9% of
54); III, 12 (6% of 192); IV, ﬁve (25% of 20); V, 18
(14% of 131); VI, ﬁve (38% of 13); VII, one (33% of
three); and VIII, two (67% of three). The molec-
ular serotypes identiﬁed by mPCR ⁄RLB were the
same as those assigned previously by conven-
tional serotyping for 590 (99%) of 596 isolates for
which both results were available. Six (0.9%)
isolates gave discordant results as follows: con-
ventional serotype (CS) Ia ⁄MS V; CS Ib ⁄MS II;
CS V ⁄MS III (two isolates); CS II ⁄MS indetermi-
nate; and CS Ib ⁄MS indeterminate.
All 76 isolates with discordant or missing
conventional serotyping results were retested
using individual serotype-speciﬁc PCR and con-
ventional serotyping, which conﬁrmed the
mPCR ⁄RLB results for three isolates with previ-
ously discordant results; 70 remained non-type-
able by conventional serotyping and the
mPCR ⁄RLB results were conﬁrmed by serotype-
speciﬁc PCR. Initial conventional serotyping
results were conﬁrmed for the three remaining
isolates with discordant results, but serotype-
speciﬁc PCRs were positive in each case for two
serotypes. These isolates were subcultured and
several single colonies of each were tested sepa-
rately using serotype-speciﬁc PCRs. Each of these
single colony subcultures gave a positive result in
only one serotype-speciﬁc PCR, and these results
were conﬁrmed, using one representative of each
serotype, by conventional serotyping. These re-
sults indicate that the original isolates were mixed
cultures. The mixed cultures were from patients
in different age groups and involved various
serotypes as follows: WCBA, serotypes Ia and V;
EO, serotypes II and III; and other adults,
serotypes Ib and V.
Distribution of molecular serotypes among
patient groups
MS Ia and III were the most commonly identiﬁed
serotypes among isolates from infants and chil-
dren (Table 2). MS V was signiﬁcantly more
common (102 ⁄ 392, 26% vs. 29 ⁄ 274, 11%;
p <0.001) and MS III was signiﬁcantly less com-
mon (81 ⁄ 392, 21% vs. 111 ⁄ 274, 41%; p <0.001) in
adults than in infants and children. For MS III,
this difference was attributable mainly to a sig-
niﬁcantly higher proportion of serosubtype III-2
isolates in the LO group as compared with all
other groups (25 ⁄ 104, 24% vs. 24 ⁄ 562, 4%;
p <0.001). Serosubtype III-2 was also signiﬁcantly
more common in the LO than in the EO group
(25 ⁄ 104, 24% vs. 14 ⁄ 154, 9%; p 0.005). MS II was
signiﬁcantly less common in the LO group than in
all other groups combined (1 ⁄ 104, 1% vs. 53 ⁄ 562,
9%; p 0.006) or the EO group (1 ⁄ 104, 1% vs.
16 ⁄ 154, 10%; p 0.005).
Differences between isolates in the EO and
WCBA groups were similar to those between the
combined paediatric and adult groups; i.e., there
were signiﬁcantly more MS V isolates (13 ⁄ 154,
8% vs. 18 ⁄ 94, 19%; p 0.031) and somewhat, but
not signiﬁcantly, fewer MS III isolates (54 ⁄ 154,
35% vs. 20 ⁄ 94, 21%; p 0.09) in the latter group.
There was no signiﬁcant difference in the distri-
bution of serotypes between WCBA and other
adults.
AR markers
The most frequently identiﬁed AR marker in all
groups was tetM, which was present in 560 (84%)
isolates (Table 3), most of which (360 ⁄ 560, 64%)
Table 2. Distribution of molecular serotypes of group B
streptococci according to patient category
MS ⁄msst
Paediatric groupsa, n (%)
Adult groupsb,
n (%)
Total,
n (%)cEO LO Children WCBA Other
Ia 46 (30) 25 (24) 5 (31) 29 (31) 58 (19) 163 (24)
Ib 19 (12) 14 (13) 1 (6) 15 (16) 38 (13) 87 (13)
II 16 (10) 1 (1)d 0 7 (7) 30 (10) 54 (8)
III-1 30 (19) 20 (19) 4 (25) 12 (13) 44 (15) 110 (17)
III-2 14 (9) 25 (24)e 1 (6) 5 (5) 4 (1) 49 (7)
III-3 3 (2) 2 (2) 2 (13) 2 (2) 6 (2) 15 (2)
III-4 7 (5) 3 (3) 0 1 (1) 7 (2) 18 (3)
III totalf 54 (35) 50 (48) 7 (44) 20 (21) 61 (20) 192 (29)
IV 3 (2) 1 (1) 0 2 (2) 14 (5) 20 (3)
Vg 13 (8) 13 (13) 3 (19) 18 (19) 84 (28) 131 (20)
VI 2 (1) 0 0 2 (2) 9 (3) 13 (2)
VII 0 0 0 1 (1) 2 (1) 3 (0.5)
VIII 1 (1) 0 0 0 2 (1) 3 (0.5)
Total 154 (100) 104 (100) 16 (100) 94 (100) 298 (100) 666 (100)
MS, molecular serotype; msst, molecular serosubtype (MS III only); see text for
deﬁnition of serosubtype; EO, early onset; LO, late onset; WCBA, women of
childbearing age.
aPaediatric groups: EO (neonates), aged <7 days; LO (infants), aged 7–90 days;
children, aged 90 days to 14 years.
bAdult groups: WCBA, aged 15–45 years; other adults, males aged >14 years;
females, aged >45 years.
cIsolates from three of 663 patients were mixtures of two serotypes; each was
treated as a separate isolate.
dMS II: LO (1 ⁄ 104; 1%) vs. EO (16 ⁄ 154; 10%), p 0.005; LO (1 ⁄ 104; 1%) vs. all other
groups (53 ⁄ 562; 9%), p 0.006.
emsst III-2: LO (25 ⁄ 104; 24%) vs. EO (14 ⁄ 154; 9%), p 0.005; LO (25 ⁄ 104; 24%) vs. all
other groups (24 ⁄ 562; 4%), p <0.001.
fMS III: infants and children (111 ⁄ 274; 41%) vs. adults (81 ⁄ 392; 21%), p <0.001.
gMS V: infants and children (29 ⁄ 275; 11%) vs. adults (102 ⁄ 392; 26%), p <0.001; EO
(13 ⁄ 155; 8%) vs. WCBA (18 ⁄ 94; 19%), p 0.03.
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also contained int-Tn. Macrolide resistance genes
were found in a small proportion of isolates
(52 ⁄ 666; 8%) and each of the three relevant genes
was represented: ermB, 3.3%, ermA, 2.5% and
mefA ⁄E, 2.3%. One isolate contained both ermA
and ermB, and one contained both ermA and
mefA ⁄E. Based on previous results [7], there is
excellent correlation between the presence of any
of these genes and phenotypic resistance to
erythromycin, and the presence of ermA and ⁄ or
ermB and constitutive or inducible resistance to
clindamycin. There were no signiﬁcant differ-
ences in the distribution of resistance genes
among patient groups (Table 3).
Distribution of AR markers among molecular
serotypes
The proportions of isolates with AR markers
varied signiﬁcantly according to MS for all the
markers examined, with the exception of
mefA ⁄E (Table 4). The greatest variation was in
the prevalence of tetM and int-Tn. The majority
(214 ⁄ 223; 96%) of tetM-positive MS V and sero-
subtype III-1 isolates also contained int-Tn, but
this was true of only a small proportion (30 ⁄ 152;
20%) of tetM-positive MS Ia isolates (p <0.001).
int-Tn was found in the absence of tetM in only
16 (4%) of 376 isolates, of which a dispropor-
tionate number belonged to serosubtype III-2
(ten of 49; 20%). No AR markers were found in
73 (11%) of 666 isolates overall, but this pro-
portion varied from 3% (4 ⁄ 131) in MS V to 69%
(9 ⁄ 13) in MS VI (Table 4). Serosubtype III-2 was
the only MS ⁄ serosubtype in which none of the
isolates tested contained any of the ﬁve macro-
lide or aminoglycoside resistance genes,
whereas 52 (8%) of 617 isolates belonging to
other MS ⁄ serosubtypes contained at least one of
these genes.
Table 3. Distribution of antibiotic resistance (AR) markers
among invasive isolates of group B streptococci according
to patient category
AR
markera,b
Paediatric groups, n (%)
Adult groups,
n (%)
Total
n (%)EO LO Children WCBA Other
tetM 132 (86) 87 (84) 14 (88) 81 (86) 246 (83) 560 (84)
int-Tn 85 (55) 60 (58) 11 (69) 47 (50) 173 (58) 376 (56)
tetO 5 (3) 0 1 (6) 1 (1) 6 (2) 13 (1.9)
ermB 5 (3) 3 (3) 0 2 (2) 12 (4) 22 (3.3)c
ermA 5 (3) 0 1 (6) 1 (1) 10 (3) 17 (2.5)c
mefA ⁄E 2 (1) 1 (1) 0 1 (1) 11 (4) 15 (2.2)c,d
aphA-3 1 (1) 1 (1) 0 1 (1) 5 (2) 8 (1.2)
aad-6 1 (1) 1 (1) 0 2 (2) 7 (2) 11 (1.6)
Total 154 (100) 104 (100) 16 (100) 94 (100) 298 (100) 666 (100)
EO, early onset; LO, late onset; WCBA, women of childbearing age (for deﬁnitions,
see main text).
aAR markers encode resistance to the following antibiotics [7]: tetM and tetO,
tetracycline; ermA and ermB, macrolides, lincosamine and streptogramin B; mefA ⁄E,
14–15-member macrolide antibiotics, including erythromycin; aphA-3 and aad-6,
aminoglycosides. int-Tn is an integrase gene carried on transposons belonging to
the Tn916 group, which usually carry tetM.
bNone of the differences in frequencies of AR-related genes among patient groups
was statistically signiﬁcant.
cTwo isolates contained two macrolide resistance genes: one with ermA and ermB;
one with ermA and mefA ⁄E.
dBased on type-speciﬁc PCR, eight of 15 mef-positive isolates had mefE (personal
unpublished results).
Table 4. Distribution of antibiotic resistance (AR) markers among invasive isolates of group B streptococci according to
molecular serotype (MS)
MS
Antibiotic resistance markers, n (%)
No AR markers tetM int-Tn tetO ermB ermA mefA ⁄E aphA-3 aad-6 Total
Ia 7 (4)a 152 (93) 32 (20)b 1 (1) 1 (1) 0 7 (4) 0 0 163
Ib 19 (22) 68 (78) 57 (66) 0 0 1 (1) 1 (1) 0 1 (1) 87
II 8 (15) 40 (74) 35 (65) 4 (7) 3 (6) 2 (4) 1 (2) 0 0 54
III-1 4 (4)c 100 (91) 96 (87) 6 (5) 6 (5)d 3 (3)d 2 (2)d 4 (4) 5 (5) 110
III-2 6 (12) 33 (67) 24 (49) 0 0 (0)e,f 0 (0)e,f 0 (0)e,f 0f 0f 49
III-3 4 (27) 9 (60) 4 (27)c 0 1 (7) 0 2 (13) 0 0 15
III-4 7 (39) 10 (56) 5 (28) 0 1 (6) 0 0 0 0 18
IV 2 (10) 17 (85) 3 (15) 1 (5) 0 2 (10) 0 0 1 (5) 20
V 5 (4)g 123 (94) 118 (90) 1 (1) 10 (8)h 9 (7)e 1 (1)h 4 (3) 4 (3) 131
VI 9 (69) 4 (31) 1 (8) 0 0 0 1 (8) 0 0 13
VII 0 3 1 0 0 0 0 0 0 3
VIII 2 (67) 1 0 0 0 0 0 0 0 3
Total 73 (11) 560 (84) 376 (56) 13 (2) 22 (3) 17 (3) 15 (2) 8 (1) 11 (2) 666
aNo AR markers in Ia (7 ⁄ 163; 4%) vs. all other isolates (66 ⁄ 503; 13%); p 0.004.
bint-Tn in MS Ia (32 ⁄ 163; 20%) vs. all other isolates (344 ⁄ 503; 68%); p <0.001.
cNo AR markers in serosubtype III-1 (4 ⁄ 110; 4%) vs. all other isolates (69 ⁄ 556; 12%); p 0.013.
dAny macrolide ⁄ lincosamine resistance in MS V (28 ⁄ 131, 21%) vs. all other isolates (45 ⁄ 535; 8%); p <0.001.
eAny macrolide ⁄ lincosamine resistance in serosubtype III-2 (0 ⁄ 49) vs. all other common MS Ia, Ib, II and V and serosubtype III-1 (47 ⁄ 545; 9%); p 0.04.
fApart from serosubtype III-2, all other groups contained some isolates with at least one macrolide or aminoglycoside resistance gene (0 ⁄ 49 vs. 52 ⁄ 617; p 0.04).
gNo AR markers in MS V (5 ⁄ 131; 4%) vs. all other isolates (68 ⁄ 535; 13%); p 0.007.
hAny macrolide ⁄ lincosamine resistance in serosubtype III-1 (20 ⁄ 110; 18%) vs. all other isolates (53 ⁄ 556; 10%); p 0.02.
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Comparisons between Sydney, Australia and
New Zealand
There was a signiﬁcantly smaller proportion of
LO isolates among the isolates from Sydney as
compared with New Zealand (Table 1), which
reﬂects the fact that the CIDM does not provide
microbiology services to a specialist paediatric
centre. Because of this, comparisons between
geographical areas were made only within patient
groups. There were no signiﬁcant differences in
the distribution of molecular serotypes or AR
markers between the two countries (data not
shown), except in the EO disease group, for which
there was a signiﬁcantly higher proportion of
MS Ib isolates among isolates from New Zealand
as compared with those from Sydney (18 ⁄ 110;
16% vs. 1 ⁄ 44; 2%, p 0.03).
Comparison of isolates over time according to
country and patient group
Among isolates from Sydney, there were no
signiﬁcant differences between isolates collected
in 1996–2000 and those collected in 2001–2005
(data not shown). In New Zealand, there was a
signiﬁcant increase between 1994–2000 and
2001–2005 in the proportion of serosubtype
III-1 isolates in the EO, LO and WCBA groups
combined (5 ⁄ 69, 7% vs. 42 ⁄ 202, 21%; p 0.03),
which was associated with increases in some
AR markers. In 1994–2000, only one (1%) of 108
isolates was erythromycin-resistant (ermA) as
compared with 27 ⁄ 338 (8%) in 2001–2005
(p 0.02); of the latter, 14 (4%) had ermB, eight
(2%) had ermA and ﬁve (1%) had mefA ⁄E.
Aminoglycoside resistance markers were not
identiﬁed in 1994–2000, but were found in 1%
of isolates in 2001–2005 (0 ⁄ 108, vs. 3 ⁄ 338; p 0.33;
NS).
Comparison between blood and CSF isolates
Comparison of the distribution of MS ⁄ serosub-
types between isolates from blood (n = 608) and
CSF (n = 35), with 23 isolates from other sterile
sites excluded, revealed that MS III overall, and
serosubtypes III-2 and III-3 individually, were
signiﬁcantly more common among CSF isolates
(Table 5). A disproportionate number of CSF
isolates (20 ⁄ 35; 57%), as compared with blood
isolates (83 ⁄ 608; 14%), were from the LO group,
which is potentially a confounding factor in the
association between serosubtype III-2 and LO
disease described above. However, comparison of
MS distribution according to patient category for
blood isolates showed that only the association
between serosubtype III-2 and the LO group
remained (serosubtype III-2 in LO, 18 ⁄ 83, 22%
vs. serosubtype III-2 in all other groups, 24 ⁄ 526,
5%; p <0.001).
DISCUSSION
This is the ﬁrst comprehensive study in Austral-
asia, and one of the largest overall, of serotype
and AR distribution among invasive GBS isolates
from all age groups. A convenient mPCR ⁄RLB
method was used to characterise the isolates,
combining separate assays for identiﬁcation
of molecular serotypes [6] and detection of
AR-related genes [7] in GBS. Three (0.5%) of 605
blood cultures were shown to contain two sero-
types, as shown by indeterminate mPCR ⁄RLB
results, which were resolved by performing sero-
type-speciﬁc PCR and conventional serotyping on
subcultures of several individual colonies.
The present study demonstrated or conﬁrmed
the following signiﬁcant ﬁndings: (i) a virulent
GBS clone, represented by a subtype of sero-
type III (serosubtype III-2), was associated
strongly with LO, but not EO, GBS disease in
Table 5. Distribution of molecular serotypes ⁄ subtypes
(MS ⁄ serosubtype) of group B streptococci according to
site of isolation (blood or cerebrospinal ﬂuid (CSF))
MS or
serosubtype
CSF isolates all patients,
n (%) ⁄LO, n (%)a
Blood isolates all patients,
n (%) ⁄LO, n (%)a
Ia 4 (11) ⁄ 2 (10) 155 (25) ⁄ 23 (28)
Ib 7 (20) ⁄ 3 (15) 76 (13) ⁄ 11 (13)
II 1 (3) ⁄ 0 50 (8) ⁄ 1 (1)
III-1 9 (26) ⁄ 5 (25) 96 (16) ⁄ 14 (17)
III-2b 7 (20) ⁄ 7 (35) 42 (7) ⁄ 18 (22)c
III-3d 3 (9) ⁄ 1 (5) 11 (2) ⁄ 1 (1)
III-4 1 (3) ⁄ 1 (5) 17 (3) ⁄ 2 (2)
III totale 20 (57) ⁄ 14 (70) 166 (27) ⁄ 35 (42)
IV 0 ⁄ 0 19 (3) ⁄ 1 (1)
Vf 2 (6) ⁄ 1 (5) 125 (21) ⁄ 2 (2)
VI 1 (3) ⁄ 0 12 (2) ⁄ 0
VII 0 ⁄ 0 2 (0.3) ⁄ 0
VIII 0 ⁄ 0 3 (0.5) ⁄ 0
Total 35 (100) ⁄ 20 (100) 608 (100) ⁄ 83 (100)
LO, late onset (see text).
aNone of the differences between CSF and blood isolates in the LO group was
statistically signiﬁcant.
bMS III-2 all patients, CSF 7 ⁄ 35, 20% vs. blood 42 ⁄ 608, 7%; p 0.012.
cBlood isolates only, serosubtype III-2 in LO, 18 ⁄ 83, 22% vs. all other groups
24 ⁄ 525, 5%; p <0.001.
dMS III-3 all patients, CSF 3 ⁄ 35, 9% vs. blood 11 ⁄ 608, 2%; p 0.011.
eMS III (overall) all patients, CSF 20 ⁄ 35, 57% vs. blood 166 ⁄ 608, 27%; p 0.01.
fMS V all patients, CSF 2 ⁄ 35, 6% vs. blood 125 ⁄ 608, 21%; p 0.06 (not signiﬁcant).
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infants; (ii) the predominant GBS serotypes
(Ia, III, V) causing invasive infection in Australasia
were similar to those found in North America and
Europe; (iii) there were signiﬁcant differences in
the distribution and incidence of AR between the
two major subtypes of MS III, with serosubtype
III-1 being signiﬁcantly more common in all
groups except LO infants, and signiﬁcantly more
likely to contain AR genes than was serosubtype
III-2; (iv) there were signiﬁcant differences in the
distribution of AR markers among different
MS ⁄ serosubtypes, with serosubtype III-2 isolates
being signiﬁcantly less likely to contain erythro-
mycin or aminoglycoside resistance genes than all
other MS ⁄ serosubtypes combined; (v) the low
incidence of int-Tn in tetM-positive MS Ia isolates,
as compared with other common MS ⁄ serosub-
types, suggested that transmission of tetM inMS Ia
commonly occurs by a mechanism not involving a
transposon of the Tn916 group; (vi) erythromycin
resistancewas uncommon among invasive isolates
in the region, but has increased in New Zealand
over the past 5 years in association with a relative
increase in MS V and serosubtype III-1; and (vii)
GBS meningitis was more common among the LO
infant group than among the other patient groups,
with all majorMS ⁄ serosubtypes being represented
among recognised cases of meningitis, but MS III
(and speciﬁcally serosubtypes III-2 and III-3)
being disproportionately represented among CSF
isolates as compared with other MS ⁄ serosubtypes.
However, this does not wholly explain the strong
association of serosubtype III-2 with LO disease in
infants.
If the assumption that pregnancy is the most
common risk-factor for invasive GBS disease in
WCBA is correct, the differences in the distribu-
tion of serotypes between the EO infant and
WCBA groups suggests that the pathogenesis of
invasive disease is different in mothers and
infants in the ﬁrst week of life. While this is
plausible, and appears to be the case for infants
with LO infection, it could also indicate that the
WCBA group included a signiﬁcant proportion of
women with non-pregnancy-related risk-factors
similar to those in other adults.
Previous studies have reported an association
between neonatal sepsis and a virulent GBS clone
belonging to multilocus sequence type (ST)17
[11–14] and serotype III. Typically, this virulent
strain carries genetic markers, including the
group II intron, GBSi1, typical of a pathogenicity
island-like region that shares homology with
Streptococcus pyogenes [14–17]. In a recent study
from Oxford, UK [18], ST17 was the only ST
identiﬁed signiﬁcantly more frequently among
invasive isolates from neonates than among vag-
inal isolates from pregnant woman. The differ-
ence was considerably more marked for LO
infants (18 ⁄ 45, 40% vs. 19 ⁄ 190, 10%; OR 6.0;
95% CI 2.6–13.8; p <0.00001) than for EO infants
(15 ⁄ 64, 23% vs. 19 ⁄ 190, 10%; OR 2.8; 95% CI 1.2–
6.2; p 0.004) isolates. The fact that all ST17 isolates
belonged to serotype III, but that many sero-
type III isolates belonged to other STs (mainly
ST19), indicated that the invasiveness of ST17 is
not caused solely by the serotype III capsule [18].
Although the present study did not compare
invasive with vaginal-colonising isolates, the
results obtained support this conclusion. It has
been shown previously that the virulent ST17
clone corresponds to serosubtype III-2 [12], and
that it is associated particularly with LO neonatal
sepsis, but rarely causes invasive disease in adults
[8]. The present, much larger, study conﬁrms a
signiﬁcant association between serosubtype III-2
and LO, but not EO, disease in infants, suggesting
signiﬁcant differences in pathogenesis between
these two types of neonatal GBS disease.
Serosubtype III-2 is distinguished easily from
the more common serosubtype III-1, which con-
tains IS1548 and IS1381, but not GBSi1, usually
belongs to ST19, is a common vaginal coloniser,
and is equally common in cases of EO and LO
infant and adult GBS disease [8,12]. Although
these two major MS III subtypes have antigeni-
cally similar polysaccharide capsules, there are
consistent cps sequence differences that allow
them to be distinguished [19].
Meningitis is more common among infants
with LO disease than in other groups, but this
does not wholly explain the strong association
between serosubtype III-2 and LO disease. How-
ever, the possibility cannot be excluded that some
cases of meningitis were not identiﬁed because
lumbar punctures were not performed, or because
blood, but not CSF, isolates were referred for
serotyping. The present study demonstrates that
serosubtype III-2 is signiﬁcantly less likely than
other molecular serotypes and serosubtype III-1
to carry AR-associated genes, especially macro-
lide or aminoglycoside resistance genes. Macro-
lide resistance is uncommon in Australasia, and
further investigation is needed to determine
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whether this is also true in regions in which the
overall incidence of AR is higher.
The relatively low overall incidence (8%) of AR
in the present study was similar to that reported
in some previous studies (8–11%) [7,20–23], but
lower than that reported in others (16–30%)
[7,24–32]. A recent increase in antibiotic resistance
among GBS in the USA was associated with the
emergence and spread of a single serotype V
clone [25], in which macrolide resistance was
signiﬁcantly more common than in other sero-
types. Although the prevalence of macrolide and
aminoglycoside resistance genes in MS V was
moderately high (21%) in the present study, it
was not signiﬁcantly higher than in serosubtype
III-1 (18%) or MS II (11%). Neither macrolide nor
aminoglycoside resistance markers were identi-
ﬁed among New Zealand isolates collected before
1998, but ermB was found with increasing fre-
quency between 2001 and 2004, and was associ-
ated with increases (not individually statistically
signiﬁcant) in MS V and serosubtype III-1. In
Australia, there was no signiﬁcant difference
between the two periods.
On the basis of the present data, a tetravalent
Ia, Ib, III, V vaccine could potentially provide
protection against 90% of invasive infections in
infants, and 87% of those in WCBA in Australia
and New Zealand [33]. Alternatively, the use of
common protein antigens with a limited number
of group-speciﬁc polysaccharides would increase
the protective range [34].
The mPCR ⁄RLB method used in this study is
simple, inexpensive, reproducible, objective and
speciﬁc. Virtually all isolates are typeable with
mPCR ⁄RLB, whereas a signiﬁcant proportion
(11%) of isolates in this study, as in previous
studies, were non-typeable or difﬁcult to type by
conventional serotyping [35,36]. The present
study provided data concerning serotype and
AR distribution among invasive GBS isolates in
Australasia, and demonstrates the utility of this
simple typing method, which would be suitable
for routine surveillance in other countries.
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